Newswire (Published: Tuesday, October 17, 2017, Received: Thursday, October 12, 2017, 5:10:27 PM CDT)

Word Count: 447

Findings on Prostate Cancer Detailed by P. Moise and Co-Authors (Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings)

By a News Reporter-Staff News Editor at Cancer Weekly -- Fresh data on Oncology - Prostate Cancer are presented in a new report. According to news originating from Paris, France, by NewsRx correspondents, research stated, "We developed a conceptual model to define key concepts associated with patients' experiences with the signs, symptoms, and impacts of non-metastatic castration-resistant prostate cancer (M0-CRPC). A targeted review of peer-reviewed literature, and other publicly available information, identified and categorized symptoms and impacts related to early-stage prostate cancer."

Our news journalists obtained a quote from the research, "Semi-structured interviews with five clinical experts helped determine the most relevant and important concepts for patients with M0-CRPC. Qualitative interviews with 17 patients with M0-CRPC identified the most frequently experienced symptoms and impacts, and their degree of interference with patients' lives. The findings from these three lines of evidence were summarized in a conceptual model. Literature searches identified mainly urinary, intestinal, and sexual symptoms. Experts noted the symptoms most frequently mentioned by patients include erectile dysfunction, loss of sexual desire or interest, incontinence/leaking, urgency, and hot flashes. Patient interviews confirmed the high frequency of erectile dysfunction, loss of libido, urinary urgency, and incontinence. The most frequently mentioned impacts expressed by patients were the need to monitor/plan for urinary frequency, interference with/restriction of daily activities, and frustration or anxiety over diagnosis, symptoms, or treatment. Symptoms and impacts most frequently experienced by patients were typically not those with the greatest effects on their lives; rather, those with the greatest consequences were related to treatment. The leading concerns associated with M0-CRPC were related to voiding and sexual dysfunction."

According to the news editors, the research concluded: "The most relevant symptoms and impacts expressed by patients may be a consequence of therapy rather than of the disease."

For more information on this research see: Symptoms and Impacts in Non-Metastatic Castration-Resistant Prostate Cancer: Qualitative Study Findings. Patient-Patient Centered Outcomes Research, 2017;10(5):567-578. Patient-Patient Centered Outcomes Research can be contacted at: Adis Int Ltd, 5 The Warehouse Way, Northcote 0627, Auckland, New Zealand (see also Oncology - Prostate Cancer).

The news correspondents report that additional information may be obtained from P. Moise, QuintilesIMS Inc, F-92594 Paris, France. Additional authors for this research include E.L. Tomaszewski, R.N. Krupnick, J. Downing, M. Meyer, S. Naidoo and S. Holmstrom.

Keywords for this news article include: Paris, France, Europe, Prostatic Neoplasms, Prostate Cancer, Oncology.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Companies

Northcote Limited

Places

Australia and New Zealand
Western Europe
France
New Zealand
Europe
Oceania
Paris
Auckland

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Sexual Disorders